Abstract:Abstract: The tumor suppressor protein p53, a transcription factor playing a key role in cancer prevention, interacts with DNA as its primary means of determining cell fate in the event of DNA damage. When it becomes mutated, it opens damaged cells to the possibility of reproducing unchecked, which can lead to formation of cancerous tumors. Despite its critical role, therapies at the molecular level to restore p53 native function remain elusive, due to its complex nature. Nevertheless, considerable information has been amassed, and new means of investigating the problem have become available. Objectives: We consider structural, biophysical, and bioinformatic insights and their implications for the role of direct and indirect readout and how they contribute to binding site recognition, particularly those of low consensus. We then pivot to consider advances in computational approaches to drug discovery. Materials and methods: We have conducted a review of recent literature pertinent to the p53 protein. Results: Considerable literature corroborates the idea that p53 is a complex allosteric protein that discriminates its binding sites not only via consensus sequence through direct H-bond contacts, but also a complex combination of factors involving the flexibility of the binding site. New computational methods have emerged capable of capturing such information, which can then be utilized as input to machine learning algorithms towards the goal of more intelligent and efficient de novo allosteric drug design. Conclusions: Recent improvements in machine learning coupled with graph theory and sector analysis hold promise for advances to more intelligently design allosteric effectors that may be able to restore native p53-DNA binding activity to mutant proteins. Clinical relevance: The ideas brought to light by this review constitute a significant advance that can be applied to ongoing biophysical studies of drugs for p53, paving the way for the continued development of new methodologies for allosteric drugs. Our discoveries hold promise to provide molecular therapeutics which restore p53 native activity, thereby offering new insights for cancer therapies. Graphical abstract: Structural representation of the p53 DBD (PDBID 1TUP). DNA consensus sequence is shown in gray, and the protein is shown in blue. Red beads indicate hotspot residue mutations, green beads represent DNA interacting residues, and yellow beads represent both.

Navigating the complexity of p53-DNA binding: implications for cancer therapy

Unraveling The Allosteric Mechanism Of Four Cancer-Related Mutations In The Disruption Of P53-Dna Interaction

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities

In Silico Screening, Molecular Dynamics Simulation and Binding Free Energy Identify Single-Point Mutations That Destabilize p53 and Reduce Binding to DNA

p53's Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies

Full-atomistic Molecular Dynamics Analysis of p53 Active Tetramer

Novel Roles For P53 In The Genesis And Targeting Of Tetraploid Cancer Cells

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Unlocking the Gateway: The Spatio-Temporal Dynamics of the p53 Family Driven by the Nuclear Pores and Its Implication for the Therapeutic Approach in Cancer

Molecular dynamics-based computational investigations on the influence of tumor suppressor p53 binding protein against other proteins/peptides

Determinants of p53 DNA binding, gene regulation, and cell fate decisions

Blinded by the Light: The Growing Complexity of p53

Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

Structural modulation of p53TAD1-TAZ2 complex upon mutations and post-translational modification

Translating p53-based therapies for cancer into the clinic

At a Crossroads to Cancer: How p53-Induced Cell Fate Decisions Secure Genome Integrity

Structural effects and competition mechanisms targeting the interactions between p53 and MDM2 for cancer therapy

Decoding p53 tumor suppression: a crosstalk between genomic stability and epigenetic control?

The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants

Understanding the complexity of p53 in a new era of tumor suppression